Looking Into Colfax’s Return On Capital Employed

According to Benzinga Pro, during Q2, Colfax (NYSE:CFX) earned $75.94 million, a 23.87% increase from the preceding quarter. Colfax also posted a total of $985.93 million in sales, a 12.14% increase since Q1.

According to Benzinga Pro, during Q2, Colfax (NYSE:CFX) earned $75.94 million, a 23.87% increase from the preceding quarter. Colfax also posted a total of $985.93 million in sales, a 12.14% increase since Q1. Colfax earned $61.31 million, and sales totaled $879.21 million in Q1.

What Is ROCE?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company’s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Colfax posted an ROCE of 0.02%.

Keep in mind, while ROCE is a good measure of a company’s recent performance, it is not a highly reliable predictor of a company’s earnings or sales in the near future.

ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Colfax is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

For Colfax, the positive return on capital employed ratio of 0.02% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.

Upcoming Earnings Estimate

Colfax reported Q2 earnings per share at $0.56/share, which beat analyst predictions of $0.53/share.

Total
0
Shares
Related Posts
Read More

Chemours: Q4 Earnings Insights

Chemours (NYSE:CC) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Chemours missed estimated earnings by 11.96%, reporting an EPS of $0.81 versus an estimate of $0.92.

CC

Read More

Veracyte: Q2 Earnings Insights

Veracyte (NASDAQ:VCYT) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte beat estimated earnings by 40.91%, reporting an EPS of $-0.13 versus an estimate of $-0.22.

VCYT